A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)
NCT02082899
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
150
Enrollment
INDUSTRY
Sponsor class
Conditions
Allergic Conjunctivitis
Interventions
DRUG:
Active Comparator EBI-005 5 mg/mL
DRUG:
Placebo Comparator
Sponsor
Eleven Biotherapeutics